GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET

Company Participants

Christian Dinneen-Long - General Counsel

Harout Semerjian - CEO

Edwin Rock - CMO

Brian Hahn - CFO

Conference Call Participants

Roger Song - Jefferies

Operator

Good morning, and thank you for joining the GlycoMimetics, Q2 2023 Earnings Call. At this time all participants are in listen-only mode. Following management's remarks, we will hold a question-and-answer session. [Operator Instructions].

I would now like to turn the call over to Christian Dinneen-Long, Company Counsel at GlycoMimetics. Please go ahead.

Christian Dinneen-Long

Good morning. Today we will review our business updates and financial results for the quarter ended June 30, 2023. The press release we issued this morning is available on the company's website at glycomimetics.com. This call is being recorded, and the dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the investors section of the company's website.

Joining me on the call today from GlycoMimetics are Harout Semerjian, Chief Executive Officer Brian Hahn, Chief Financial Officer, and Dr. Edwin Rock, Chief Medical Officer.

Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include but are not limited to statements about the company's product candidate, uproleselan, or our other pipeline programs, along with statements about the conduct of and our collaborators' clinical trials, and planned or potential regulatory agency interactions or submissions, development plans and activities, pre-commercialization preparations, the company's operations, cash position and runway, and our expectations regarding data from clinical trials.

Such statements represent management's judgment and intention as of today, and involve assumptions, risks and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company please refer to our filings with the SEC, which are available from the SEC or through the GlycoMimetics website.

I'll now turn the call over to Harout.

Harout Semerjian

Thank you, Christian. Good morning, everyone. This is a transformational time for our company as we continue to advance our clinical pipeline, and to evolve ourselves into a commercial stage organization.

Today, we would like to highlight three major advancements that position us well for a catalyst rich upcoming 12 months. First, the FDA cleared a protocol amendment for our Phase 3 uproleselan study that will enable us to report top line results by the end of Q2 2024. Second, we continued to broaden our clinical development strategy for uproleselan by moving forward with our pediatric development plan. And third, we plan to further expand our clinical pipeline and initiate a first-in-human Phase 1a study for GMI-1687 in the third quarter of this year. These three areas of progress each represent potential long term value drivers for our company.